Request Copyright Permission

Inhaled Tuberculosis Therapy: Primary, Adjunct or Kaput?

Traini D.

RDD Asia 2016. Volume , 2016: 57-70.

Abstract:

While standard oral or injectable anti-tuberculosis (TB) drug therapies may be comparatively inexpensive, it is evident that these approaches are not favored among patients and health care professionals, with varying success and sometimes failure, especially with respect to multi-drug resistance. Inhalation therapy, used as primary or adjunct to the current standard therapy for TB, may hold the key as a potential new therapy that could bring improved health benefits. This article reviews innovation in the area of inhaled TB therapeutics over the past 10 years, and questions whether inhalation is a viable approach to primary treatment, a useful adjunct therapy to conventional oral administration or perhaps a non-starter?